Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Far-right German youth group delegates seek deportations, remigration - 2I watched more than 500 new movies this year. These are the 25 best ones.
- 3Vote in favor of your Favored Kind of Scarf
- 4Instructions to Floss Appropriately and Forestall Gum Sickness
- 5Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- Investigating the Medical advantages of Aloe Vera
- In blow to Lula, Brazil Congress revives controversial environmental bill
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Illumina unveils dataset to speed up AI-powered drug discovery
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Vote In favor of Your Number one Sort Of Blossoms
- 6 Famous kind of practice on the planet
- Israel’s mixed messaging on Christmas draws controversy
